Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PDS BiotechnologyFRA:EU6 -2.40%31 EPS without NRI is €-0.58 as of Mar. 2026. GuruFocus rates FRA:EU6 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,168 Biotechnology companies, PDS Biotechnology ranks better than 54.37% on this metric.
PDS Biotechnology's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-0.11.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.58.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for PDS Biotechnology's EPS without NRI or its related term are showing as below:
FRA:EU6'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -78.6 Med: 21.9 Max: 70.1
Current: 19.7
FRA:EU6's 3-Year EPS without NRI Growth Rate is ranked better than 54.37% of 1168
companies
in the Biotechnology industry
Industry Median: 16.4
vs FRA:EU6: 19.70
PDS Biotechnology's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.11.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.58.
PDS Biotechnology (FRA:EU6) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
PDS Biotechnology EPS without NRI Related Terms
PDS Biotechnology EPS without NRI Historical Data
* Premium members only.
The historical data trend for PDS Biotechnology's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EU6 vs LTRN, AURX, VERU: EPS without NRI Comparison
For the Biotechnology subindustry, PDS Biotechnology's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDS Biotechnology PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDS Biotechnology's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where PDS Biotechnology's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDS Biotechnology (FRA:EU6) has a EPS without NRI of €-0.58 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on PDS Biotechnology and its competitors. According to the industry distribution chart, PDS Biotechnology ranks #533 out of 1168 companies in the Biotechnology industry, placing it in the top 45.6%.
Is PDS Biotechnology's EPS without NRI too high?
PDS Biotechnology's current EPS without NRI is €-0.58. Based on the distribution chart, PDS Biotechnology ranks #533 out of 1168 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PDS Biotechnology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's EPS without NRI compare to LTRN and AURX?
According to the Biotechnology industry distribution chart, PDS Biotechnology ranks #533 out of 1168 companies for EPS without NRI. This puts PDS Biotechnology in the upper half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on PDS Biotechnology and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PDS Biotechnology's current EPS without NRI is €-0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (FRA:EU6) has a current EPS without NRI of €-0.58. The current EPS without NRI is €-0.58. PDS Biotechnology's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For PDS Biotechnology (FRA:EU6), the current EPS without NRI is €-0.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
31GF Score
Get the complete analysis for FRA:EU6
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EU6 has been successfully added to your 
